N/A N=79 Empowering Patients' Lung Cancer Screening Uptake
Lung Cancer
Primary: Order of LDCT — 50 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=152 Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
Lung Cancer · Precancerous Condition
Primary: Change in Average (Follow-up - Baseline) From All Biopsies — -0.23; -0.02 WHO Units
Phase 2 N=107 Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
Lung Cancer · Tobacco Use Disorder
Primary: Urinary Levels of Biomarkers of NNK Metabolism — 42.8; 0.36; 0.28; 49.7 pmol/mg creatinine
N/A N=80 Testing Informed Decision Making in Lung Cancer Screening
Lung Cancer
Primary: Number of Patients Who Received a Low Dose CT Scan of the Chest — 18 Participants
Phase 3 N=1,561 Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
Lung Cancer
Primary: Incidence Rate of Second Primary Lung Tumor — 1.30; 1.62 cases/100 person years — p=0.294
Phase 2 N=92 Pioglitazone for Lung Cancer Chemoprevention
Lung Cancer · Endobronchial Dysplasia
Primary: 6-month Histology Score — 3.07; 3.71 Units on a scale — p=0.53
Phase 3 N=53,454 National Lung Screening Trial (NLST) Screening
Lung Cancer
Primary: Lung Cancer Deaths — 356; 443 Participants — p=0.004
Phase 2 N=43 Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers
Lung Cancer
Primary: Change From Baseline in Bronchial Dysplasia Index at 12 Months — 1.67; 1.62; 1.55; 1.48 score — p=0.452
Phase 2 N=178 Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease
Lung Cancer Prevention
Primary: Change in Urinary 8-hydroxydeoxyguanosine Levels — 2.36; 5.20; -1.08 ng/mg creatinine
Phase 2 N=61 Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Precancerous Condition · Stage I Non-small Cell Lung Cancer · Tobacco Use Disorder
Primary: Percentage of Participants With Response Determined by Change in Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples Before and After Treatment…
Phase 2 N=202 Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer
Lung Cancer
Primary: Number CT- Detected Lung Nodules by Participant — 12; 14; 26; 19 lung nodules
N/A N=41 Tobacco Treatment in the Context of Lung Cancer Screening
Smoking Cessation
Primary: End of Treatment Abstinence Rates — 3; 0 Participants
Phase 2 N=85 Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Non-small Cell Lung Cancer · Squamous Lung Dysplasia
Primary: Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on…
N/A N=242 Community Support Program for Lung Cancer Screening
Lung Cancer · Behavior
Primary: Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants — 88; 68; 64 % of lcs appointment attendance
N/A N=1,200 Patient Navigation for Lung Screening at MGH Community Health Centers
Lung Cancer
Primary: Chest CT Completion — 124; 138 Participants
N/A N=944 Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment
Smoking Reduction · Tobacco Use · Tobacco Smoking
Primary: Self-reported Smoking Abstinence — 50; 51 Participants — p=0.83
N/A N=140 Incorporating Veterans' Preferences Into Lung Cancer Screening Decisions
Lung Cancer Screening
Primary: Decisional Conflict — 25.7; 29.9 units on a scale — p=0.18
N/A N=1,219 Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening
Early Detection of Cancer · Lung Neoplasms
Primary: Number of Participants With Lung Cancer Screening (LCS) Care-Gap Closed — 588 Participants
N/A N=9 Designing an Implementation Strategy for Lung Screening and Smoking Cessation Treatment in Community Health Centers
Smoking Cessation
Primary: Feasibility of Intervention Measure — 4 units on a scale
N/A N=40 Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding
Smoking, Cigarette · Breastfeeding
Primary: Number of Participants With Smoking Abstinence — 8; 3 Participants
N/A N=16 Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
Lung Cancer · Precancerous Condition · Tobacco Use Disorder
Primary: Grade III-IV Toxicities or Any Grade II Toxicities Lasting More Than 2 Weeks — 1; 0; 0; 0 participants
N/A N=97 Assessing Social Determinants of Health to Increase Cancer Screening
Lung Cancer
Primary: Lung Cancer Screening Uptake — 1; 5 Participants
Phase 2 N=40 Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
Lung Non-Small Cell Carcinoma · Stage I Lung Cancer AJCC v8 · Stage IA1 Lung Cancer AJCC v8
Primary: 6-month CT Assessment (Tumor Response Per mRECIST) — 1; 36; 2; 1 Participants
Phase 4 N=642 Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)
Smoking, Tobacco
Primary: Number of Participants With Self-reported Past 7-day Smoking Abstinence — 12; 10; 12; 15 Participants
Phase 2 N=367 Gain-framed Messages and NRT for Lung Cancer Screening Patients
Lung Cancer Screening · Smoking Cessation
Primary: Smoking Cessation - Available Data — 15; 19 Participants
N/A N=520 Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
Lung Cancer
Primary: Rate of Moderate to High Arsenic Level in Cases and Controls — 0.04; 0.04 mcg/dL
N/A N=6,125 Lung Cancer Screening Eligibility Assessment
Lung Cancer
Primary: Full Survey Completion — 358; 381; 383; 389 Participants
N/A N=39 Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
Lung Cancer
Primary: To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. — 0 participants
Phase 3 N=709 Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality
Non Small Cell Lung Cancer
Primary: Lung Cancer Recurrence or Mortality - 2 Years — 80; 85 Participants — p=0.94
N/A N=76 National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
Non-small Cell Lung Cancer
Primary: Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations — 80; 0; 50; 28.6 percentage of participants